Neostigmine influences the L-dopa-induced extracellular dopamine levels in the striatum

Brain Research

Volumn 856, Issue 1-2, 2000, Pages 250-253

  Izurieta Sánchez, Patricia ^a   Jonkers, Nadine ^a   Sarre, Sophie ^a   Ebinger, Guy ^b   Michotte, Yvette ^a  

^a PHARMACEUTICAL INSTITUTE   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Acetylcholine; Dopamine; Levodopa; Neostigmine

Indexed keywords

ACETYLCHOLINE; CHOLINESTERASE INHIBITOR; DOPAMINE; LEVODOPA; NEOSTIGMINE;

ANIMAL EXPERIMENT; CONTROLLED STUDY; CORPUS STRIATUM; DECARBOXYLATION; DOPAMINE RELEASE; DRUG EFFECT; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SHORT SURVEY;

EID: 0033982450     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(99)02398-7     Document Type: Article

References (15)

1. M. Chesselet, Presynaptic regulation of neurotransmitter release in the brain; facts and hypothesis, Neuroscience 12 (1984) 347-375.
2. G. Cuadra, K. Summers, E. Giacobini, Cholinesterase inhibitor effects on neurotransmitters in rat cortex in vivo, J. Pharmacol. Exp. Ther. 270 (1994) 277-284.
3. G. Damsma, B. Westerink, L. DeVries, A. Horn, The effect of systemically applied cholinergic drugs on the striatal release of dopamine and its metabolites, as determined by an automated brain dialysis in conscious rats, Neurosci. Lett. 89 (1988) 254-349.
4. P. DeBoer, B. Westerink, A. Horn, The effect of acetylcholinesterase inhibition on the release of acetylcholine from the striatum in vivo: interaction with autoreceptor responses, Neurosci. Lett. 116 (1990) 357-360.
5. P. DeBoer, E. Abercrombie, Physiological release of striatal acetylcholine in vivo: Modulation by D1 and D2 dopamine receptor subtypes, J. Pharmacol. Exp. Ther. 277 (1996) 775-783.
6. J. Girault, U. Spampinato, H. Savaki, J. Glowinski, M. Besson, In vivo release of [ H]-y-aminobutyric acid in the rat neostriatum: I. Characterization and topographical heterogeneity of the effects of dopaminergic and cholinergic agents, Neuroscience 19 (1986) 11011108.
7. P. Izurieta-Sánchez, S. Sarre, G. Ebinger, Y. Michotte, Effect of trihexyphenidyl, a non-selective antimuscarinic drug on the decarboxylation of L-dopa in hemi-Parkinson rats, Eur. J. Pharmacol. 353 (1998)33-42.
8. P. Izzo, J. Bolam, Cholinergic synaptic input to different parts of spiny striatonigral neurons in the rat, J. Comp. Neurol. 269 (1988) 219-234.
9. M. Mavridis, M. Rogard, M. Besson, Chronic blockade of muscarinic cholinergic receptors by systemic trihexyphenidyl (Arlane (R)) administration modulates but does not mediate the dopaminergic regulation of striatal prepropeptide messenger RNA expression, Neuroscience 66 (1995) 37-53.
10. M. Marione, D. Amstrong, S. Young, P. Groves, Ullrastructural examinalion of enkephalin and subslance P inpul to cholinergic neurons within the rat neostriatum, Brain Res. 594 (1992) 253-262.
11. E. Moor, E. Schirm, J. Jacso, B. Weslerink, Effecls of neosligmine and alropine on basal and handling-induced acelylcholine output from venlral hippocampus, Neuroscience 82 (1998) 819-825.
12. S. Sarre, G. Ebinger, Y. Micholle, Levodopa biotransformation in hemi-Parkinson rais: effect of dopamine receptor agonists and anlagonists, Eur. J. Pharmacol. 296 (1996) 247-260.
13. I. Smolders, S. Sarre, C. Vanhaesendonck, G. Ebinger, Y. Michotte, Extrastriatal dopamine and glutamate after decortication and kainate receptor stimulation, as measured by microdialysis, J. Neurochem. 66 (1996) 2373-2380.
14. J. Van Der Heyden, C. Venema, J. Korf, In vivo release of endoge-nous γ-aminobutyric acid from rat striatum: effects of muscimol, oxotremorine, and morphine, J. Neurochem. 34 (1980) 1648-1653.
15. M. Xu, F. Mizobe, T. Yamamoto, T. Kato, Differential effects of M1 and M2 muscarinic drugs on striatal dopamine release and metabolism in freely moving rats, Brain Res. 495 (1989) 232-242.